Table 3.
Annual proton pump inhibitor (PPI) use in packages and in DDDs in 2018, number of proton pump inhibitor users of certain active ingredients, and sales standardized by number of users (based on the public database of the National Health Insurance Fund of Hungary).
| ATC | Active Ingredient | Package number | Number of DDDs | Number of PPI users* | Average package number per user per year | Average number of DDDs per user per year |
|---|---|---|---|---|---|---|
| A02BC01 | omeprazole | 225 518 | 6 817 868 | 54 739 | 4.12 | 124.55 |
| A02BC02 | pantoprazole | 4 603 004 | 107 216 453 | 663 339 | 6.94 | 161.63 |
| A02BC03 | lansoprazole | 417 055 | 10 595 214 | 57 440 | 7.26 | 184.46 |
| A02BC04 | rabeprazole | 596 482 | 15 763 302 | 94 218 | 6.33 | 167.31 |
| A02BC05 | esomeprazole | 1 282 824 | 39 386 331 | 226 502 | 5.66 | 173.89 |
| All PPI (A02AB) | 7 124 883 | 179 779 168 | **1 096 238 | 6.50 | 164.00 | |
*user: person who purchased a prescribed proton pump inhibitor product (of the given active ingredient) at least once a year.
**: estimation as sum of individual active agents users.